This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Medical Product Stocks to Buy From a Recovering Industry
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com featured highlights include Skechers, Walmart, Haemonetics, AZZ and BOK Financial
by Zacks Equity Research
Skechers, Walmart, Haemonetics, AZZ and BOK Financial have been highlighted in this Screen of The Week article.
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
McKesson (MCK) Gains 26% YTD: What's Driving the Rally?
by Zacks Equity Research
McKesson's (MCK) shares have risen year to date on the back of strong fundamentals. Rising volumes of prescription and specialty drugs boost the top line.
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
by Zacks Equity Research
DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.
Buy 5 Stocks With Upgraded Broker Ratings for Robust Returns
by Swayta Shah
Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Skechers (SKX), Walmart (WMT), Haemonetics (HAE), AZZ Inc. (AZZ) and BOK Financial (BOKF).
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
Best Momentum Stocks to Buy for June 6th
by Zacks Equity Research
HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 6, 2024.
New Strong Buy Stocks for June 6th
by Zacks Equity Research
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.
These 3 Companies Boast Bright Outlooks
by Derek Lewis
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
Best Momentum Stocks to Buy for June 4th
by Zacks Equity Research
CAMT, HAE and NMM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2023.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Top GARP Picks for Your Portfolio Based on PEG Ratio
by Urmimala Biswas
Here are the five PEG-based GARP stocks that fit our screening criteria - DBX, HAE, PDD, BTG and ATGE.
Here's Why Haemonetics (HAE) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
by Shaun Pruitt
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
Best Momentum Stocks to Buy for May 28th
by Zacks Equity Research
MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Buy Haemonetics (HAE) Stock Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.